Logo

Vertex Reports Health Canada's Acceptance of Trikafta's NDA for Priority Review to Treat Cystic Fibrosis

Share this

Vertex Reports Health Canada's Acceptance of Trikafta's NDA for Priority Review to Treat Cystic Fibrosis

Shots:

  • Vertex’ new drug submission for Trikafta has been accepted for Priority Review by Health Canada for the treatment of CF in people aged ≥12yrs.
  • With PR- the conventional review timeline of 300 days is reduced to 180 days. The expected Health Canada’s approval is in H1’21
  • Trikafta is a triple combination regimen used to treat CF in patients aged ≥12yrs. who have at least one copy of the F508del mutation in the CFTR gene

 ­ Ref: Businesswire | Image: Vertex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions